Table 2.
Cancer control outcomes.
| Characteristics | No (%) | p-Value a | |||
|---|---|---|---|---|---|
| Patients (n = 67) |
Cases (n = 74) |
Toxicity (n = 34) |
No toxicity (n = 40) |
||
|
PSA response
Yes No |
50/64 (78) 14/64 (22) |
56/70 (80) 14/70 (20) |
25/32 (78) 7/32 (22) |
31/38 (82) 7/38 (18) |
0.8 |
|
Local control
1 year 2 years |
41/42 (98) 24/26 (92) |
47/48 (98) 26/28 (93) |
17/17 (100) 10/10 (100) |
30/31 (97) 16/18 (89) |
>0.99 0.5 |
|
Progression-free survival
1 year 2 years |
45/59 (76) 19/39 (49) |
51/65 (78) 22/44 (50) |
24/29 (83) 10/20 (50) |
27/36 (75) 12/24 (50) |
0.6 >0.99 |
|
Overall survival
1 year 2 years |
66 (99) 64 (96) |
73 (99) 71 (96) |
34 (100) 33 (97) |
39 (98) 38 (95) |
>0.99 >0.99 |
PSA, prostate-specific antigen.
a
p-Values for the comparison between patients with and without toxicity were calculated using Wilcoxon rank sum test and Fisher’s exact test for non-normally distributed continuous and categorical variables, respectively.